… )] in adults with relapsed and refractory multiple myeloma, with a primary efficacy endpoint
of ORR per independent response committee (IRC) based on International Myeloma Working …

… : Multiple myeloma is a so far incurable malignant plasma cell disorder. During the past 2
decades, treat… in relapsed or refractory multiple myeloma. Blood. 2019 Aug 22;134(8):668–77. …

… Patients with relapsed and refractory multiple myeloma (RRMM) have a poor prognosis and
limited treatment options after exposure to an immunomodulatory drug, proteasome inhibitor …

… receptor (CAR) T-cell therapy targeting B-cell … relapsed and refractory multiple myeloma
(RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat …

… prioritizing some treatments that are more effective than others in patients with relapsed/refractory
multiple myeloma. We hope this study will help centers to optimize treatment selection …

… Background: Outcomes remain poor in patients with high-risk relapsed and refractory multiple
myeloma (RRMM) receiving conventional treatments, including immunomodulatory drugs (…

… Rd in a large phase 3 study in frontline treatment (SWOG S0777), in the relapsed/refractory
multiple myeloma (RRMM) setting, only single-arm phase 2 data have been published, …

… Treatment history influences the outcomes of subsequent therapies in … with relapsed or
refractory multiple myeloma (RRMM) and needs to be considered when deciding which treatment …

… 2 Treatment schema for relapsed refractory multiple myeloma and commonly used
regimens. ASCT, autologous stem cell transplant; Bort, bortezomib; Carfil, carfilzomib; DPd, …

… -cell therapy, is effective in heavily pretreated patients … relapsed or refractory multiple
myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory …